Leia Nghiemphu

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

Christopher L. Moertel, Angela C. Hirbe, Hans Shuhaiber, Kevin Bielamowicz et autres

us (code pays fourni par la source)

CTNI-48. A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)

Patrick Y. Wen, Manmeet S. Ahluwalia, Yazmín Odia, Meredith McKean et autres

us, gb (code pays fourni par la source)

Using Qualitative Interviews to Improve Quantitative Assessments of Quality of Life in Patients with Neurofibromatosis 2 (P7-13.006)

Liesel Von Imhof, Scott Plotkin, Kaleb Yohay, Leia Nghiemphu et autres

us (code pays fourni par la source)

Supplementary Materials from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

Table 1 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

Supplementary Materials from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

Supplementary Table 2 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

us (code pays fourni par la source)

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

us (code pays fourni par la source)

Supplementary Table 2 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

Table 1 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke et autres

CTNI-65. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE TUMORS: INTERIM RESULTS OF THE BRIGATINIB TREATMENT ARM

Scott Plotkin, Jeffrey C. Allen, Dusica Babovic‐Vuksanovic, Christine T. Dinh et autres

us (code pays fourni par la source)